Artiva Biotherapeutics, Inc.(ARTV) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA Company to host webcast later this morning to discuss initial safety and translational data ...